Cooperative Agreement U24CA313507
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $717K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Illinois, USA
Similar Awards
- This Cooperative Agreement award, funded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports research to develop a non-invasive blood test for multi-cancer detection and determination of tissue of origin preceding overt cancer diagnosis. The $692,491 award, effective May 1, 2025 through April 30, 2030, will allow the University of Chicago to explore cancer-specific early epigenetic marks in circulating cell-free DNA and develop a highly sensitive...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $230,010 to the University of Chicago to develop and apply a novel epigenome sequencing platform called "Glycosylase-Implemented Epigenome Sequencing" (GLIMP-SEQ). The goal is to enable highly sensitive and accurate profiling of 5-methylcytosine (5mC), a key epigenetic marker, in degraded clinical samples such as formalin-fixed, paraffin-embedded tissues and cell-free DNA....
- The Cooperative Agreement award titled "CHARACTERIZING GENETIC RISK OF CANCER ACROSS DIVERSE POPULATIONS THROUGH MULTI-ANCESTRY EPIGENOME PROFILING AND CHROMATIN QTL DISCOVERY" is funded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393). The $720,252 award to the Dana-Farber Cancer Institute aims to identify genetic variants that influence cancer risk regulation across diverse ancestral populations. The project will profile gene...
- The National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) awarded a $3,201,530 Project Grant to the Sloan-Kettering Institute for Cancer Research to investigate the mechanisms underlying extrachromosomal DNA (ecDNA) segregation and repair in cancer. The key focus areas include: Exploring how the circular topology of ecDNA affects its function and maintenance, specifically examining the RNA-dependent physical tethering of ecDNA to mitotic chromosomes that facilitates...
- The University of Chicago received a $372,628 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) on September 12, 2025. The grant funds the development of a large-format spatial transcriptomics profiling platform, called Array-Seq, to enable detailed spatiomolecular analysis of human cancer samples. This technology aims to overcome limitations of existing spatial transcriptomics methods by increasing throughput, sample size compatibility, and...
- The National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, awarded a $734,942 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The project, titled "Aging, DNA Methylation, and Incident Cardiovascular Disease in Breast Cancer Survivors," aims to generate new blood DNA methylation data and conduct research to better...
- This federal Project Grant award of $464,212.00 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to characterize the biological mechanisms underlying the pleiotropic effects of genetic variation at the TERT/CLPTM1L locus on cancer susceptibility and aging-related traits. The University of Chicago, the awardee, will integrate large-scale genetic association data, multi-omic quantitative trait loci (QTLs) in stem/differentiating cells, and...
- The federal Project Grant award of $160,330 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) is supporting research by the University of Illinois to investigate the biochemical determinants of genome instability induced by eukaryotic topoisomerase II. The project aims to determine how the biochemical properties of topoisomerases, along with factors like chromatin structure and DNA repair pathways, influence genome instability. This research builds on the...
- The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...
- This Cooperative Agreement award for $310,185.00 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports research by New York University School of Medicine to analytically and clinically validate an Epic 900K V2 array-based methylation assay for predicting recurrence in stage II melanoma. The project aims to refine and validate a 13-probe signature that was previously found to accurately identify melanoma recurrence and mortality among stage II...